Why the study?
Cardiomyopathies have unresolved genotype-phenotype relationships and lack disease-specific treatments.
Population
hiPSC-CM and in-silico models harboring MYH7 R403Q/+, TNNT2 R92Q/+, and TNNI3 R21C/+ mutations
Comparison
Mavacamten and a novel thin filament-targeting compound across thick and thin filament variants
Design
Experimental hiPSC-CM modelling and human-based cardiac electromechanical in-silico simulation study
Authors
Loading...
May indicate mutation-specific mavacamten limits in HCM models; leaves open targeted agents for thin-filament variants pending trials.
Combining hiPSC-CMs and in-silico modeling reveals that mavacamten is effective for thick filament HCM mutations but less so for thin filament mutations, highlighting the need for targeted pharmacogenetics.
Margara et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: